Jiangsu Hengrui Pharmaceuticals Co Ltd
01276
Company Profile
Business description
Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications. It specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.
Contact
No. 38, Huanghe Road, Economic
Economic and Technological Development Zone
Jiangsu Province
Lianyugang222047
CHNT: +86 51885469805
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
20,238
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.40 | 22.00 | -0.24% |
| CAC 40 | 7,813.97 | 36.46 | -0.46% |
| DAX 40 | 24,292.55 | 51.73 | 0.21% |
| Dow JONES (US) | 44,766.33 | 243.96 | -0.54% |
| FTSE 100 | 9,144.95 | 83.46 | 0.92% |
| HKSE | 25,667.18 | 129.11 | 0.51% |
| NASDAQ | 21,059.31 | 39.29 | 0.19% |
| Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
| NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
| S&P 500 | 6,367.96 | 9.05 | 0.14% |
| S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
| SSE Composite Index | 3,605.73 | 23.43 | 0.65% |